Clinical Characteristics And Long-Term Survival Of Early Breast Cancer Cases In The American University Of Beirut Medical Center, Beirut, Lebanon.

833 Background: Based on our earlier reports of increased incidence of breast cancer in younger aged-groups at presentation, we decided to review the clinical characteristics, treatment patterns and survival data of our patients (pts) with breast cancer. Patients and Methods: Retrospective review of the medical records of all pts with breast cancer treated at our institution from 1990 to 2001. Patient demographics, clinical characteristics, pathology, staging, and treatment of 1328 pts were reviewed. Follow-up data was analyzed for 810 pts. Results: Total number was 1328 pts. 43.9% were premenopausal (pre-m), and 56.1% postmenopausal (post-m). Mean age at diagnosis was 50.8± 12 years. We had 1006 patients with early stages (In-situ, 69pts, stage I: 190 and stage II: 747 pts). 249 pts stage III and 73 pts stage IV at presentation. 1259 pts (94.8%) had infiltrative breast cancer while in-situ disease was present in only 69 pts (4.2%) Stage I pts: Total number was 190 ps. 49.5% (80 pts) of them were pre-m and 50.5% (96 pts) post-m. Mean age at diagnosis is 51.1±11.8 .57% had breast-conserving surgery and 41.3% had mastectomy. 71% had positive hormonal receptors (ER+/PR+: 47.8%, ER+/PR−16.7%, ER−/PR+ 6.5%) and 29% had negative receptors. Adjuvant chemotherapy was given to 35.4% of pts. Survival analysis showed 97.2% are still alive at 10 years.. Stage II pts: Total number 747 pts. 295 (43.9%) were pre-m and 381 (56.4%) post-m. Mean age at diagnosis was 50.7±12.4. 147 pts (20%) had breast-conserving surgery and 558 pts (78.4%) had mastectomy. 66% had positive hormonal receptors (ER+/PR+: 43.9%, ER+/PR−15.2%, ER−/PR+ 6.9%) and 34% had negative receptors. 68.3% had adjuvant chemotherapy. 93.9% are alive at 2 years, 82.9% after 5 years, and 63.1% at 10 years. Conclusions: We confirm we have a high percentage of younger-aged groups at presentation. We note a trend towards earlier stages and more breast-conserving surgeries. More than two-thirds of our pts with early disease had positive hormonal receptors. Survival is excellent at 97% at 10 years for stage I pts and good at 63.1% for stage II pts. No significant financial relationships to disclose.